Liquidia's YUTREPIA Receives FDA Fast Track Designation for Systemic Sclerosis-Associated Raynaud's Phenomenon
核心洞察
The FDA granted Fast Track designation to YUTREPIA (搜索) (treprostinil) inhalation powder for treating Raynaud's phenomenon (搜索) associated with systemic sclerosis (搜索) (SSc-RP), a condition with no currently approved U.S. therapy.
SSc-RP affects up to 90% of systemic sclerosis (搜索) patients, with an estimated 40% to 60% progressing to digital ischemic ulcers, and Liquidia estimates roughly 30,000 U.S. patients with moderate to severe symptoms.
Liquidia plans to initiate RE-WARM, a Phase 2a randomized, open-label, dose-finding study of approximately 75 adults, beginning October 2026 with primary completion targeted for February 2027.
Liquidia Corporation (搜索) (Nasdaq: LQDA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to YUTREPIA (搜索) (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon (搜索) associated with systemic sclerosis (搜索) (SSc-RP). The designation underscores the significant unmet need in a debilitating manifestation affecting up to 90% of systemic sclerosis (SSc) patients, for which no therapy is currently approved in the United States. The potential use of YUTREPIA in SSc-RP remains under clinical development, and its safety and efficacy for this indication have not been evaluated by any regulatory authority.
Disease Burden and Unmet Need
Systemic sclerosis (搜索) is a rare, chronic autoimmune disease marked by widespread vasculopathy and fibrosis of the skin and internal organs, and it carries the highest mortality of any systemic rheumatic disease. Raynaud's phenomenon (搜索) consists of recurrent, often severe vasospastic episodes that cause pain, numbness and color change in the fingers and toes. In SSc patients, these attacks are more frequent, prolonged and severe than primary Raynaud's, often progressing to digital ischemic ulcers in an estimated 40% to 60% of patients and, in recurrent cases, digital amputation.
At a 2020 FDA Patient-Focused Drug Development meeting, SSc patients identified Raynaud's attacks as among the disease's most bothersome and impactful symptoms, citing pain, functional limitation and considerable emotional distress tied to fear of ulceration and tissue loss. A central driver of SSc-RP is deficient endogenous prostacyclin production, which contributes to the vasospasm, platelet activation and vascular remodeling underlying the disease. Liquidia estimates the addressable population of SSc-RP patients with moderate to severe symptoms to be approximately 30,000 patients in the United States.
Clinical Development Plans
Dr. Rajeev Saggar, Chief Medical Officer of Liquidia, said: "Fast Track designation reflects the seriousness of this condition and the need for new options. No therapy is currently approved by the FDA specifically for SSc-RP. We are encouraged by the opportunity to evaluate whether YUTREPIA (搜索) can reduce the complications of moderate to severe Raynaud's that most affect patients' quality of life, and we are committed to advancing this program with urgency, starting with the RE-WARM study later this year."
Liquidia plans to initiate RE-WARM (NCT07748000), a Phase 2a, randomized, open-label, dose-finding study of YUTREPIA (搜索) in approximately 75 adults with SSc experiencing symptomatic Raynaud's phenomenon (搜索) attacks, at up to approximately 30 sites in the United States. The study is designed to characterize the safety and pharmacodynamics of YUTREPIA in this population, and it also explores whether treatment reduces the number, severity and impact of RP attacks. The study is expected to begin in October 2026, with primary completion targeted for February 2027.
The trial uses a parallel design with no placebo or blinding, with participants assigned to either a flexible dose-titration arm or a fixed low-dose arm. The study was first submitted on July 31, 2026, with the latest update filed on August 5, 2026, and is listed as not yet recruiting.
About YUTREPIA
YUTREPIA (搜索) is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. It was designed using Liquidia's PRINT technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, engineered for enhanced deposition in the lung following oral inhalation.
YUTREPIA (搜索) is approved for the treatment of pulmonary arterial hypertension (搜索) (PAH) and pulmonary hypertension associated with interstitial lung disease (搜索) (PH-ILD). It is not approved for the treatment of Raynaud's phenomenon (搜索) associated with systemic sclerosis (搜索), and there is no guarantee that the FDA will ultimately approve YUTREPIA for this use, even with Fast Track designation.
Regulatory Context
The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. Fast Track designation provides Liquidia with the opportunity for more frequent interactions with the FDA throughout development, the potential for rolling review of a New Drug Application, and, if relevant criteria are met, potential eligibility for Priority Review and/or Accelerated Approval.
Fast Track designation does not guarantee that YUTREPIA (搜索) will receive FDA approval for the treatment of SSc-RP, that development will proceed on the anticipated timeline, or that RE-WARM or any future study will produce favorable results.